Verastem Participates in a Conference Call With Cantor Fitzgerald
Verastem Oncology to Present at Upcoming Investor Conferences
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $8
B. Riley Adjusts Verastem Price Target to $12 From $9, Maintains Buy Rating
Verastem Oncology Announces $75M Private Placement
Express News | Verastem Inc - Private Placement Expected to Close on April 28, 2025
Express News | Verastem Inc - to Sell $24 Million in Common Stock at $7.00 per Share
Express News | Verastem Oncology Announces $75 Million Private Placement
Verastem Oncology Receives FDA Clearance for Investigational New Drug Application for Cancer Treatment
Verastem Announces U.S. IND Clearance of VS-7375
Express News | Verastem Inc - Phase 1/2a Trial in U.S. to Start Mid-2025
Express News | Verastem Oncology Announces U.S. Ind Clearance of Vs-7375, Oral Kras G12D (on/off) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
9 Health Care Stocks With Whale Alerts In Today's Session
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Jefferies Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $15
Express News | Verastem Inc : Jefferies Initiates Coverage With Buy Rating; Price Target $15
Verastem Is Maintained at Outperform by Mizuho
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $8
Express News | Verastem Inc : Mizuho Cuts Target Price to $8 From $9
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)